Neil Gross, MD, FACS, on Neoadjuvant Immunotherapy With Response-Adapted Treatment vs Standard of Care for Resectable Stage III/IV CSCC

Posted: Tuesday, April 14, 2026

Neil Gross, MD, FACS, of The University of Texas MD Anderson Cancer Center, discusses the aims of the actively enrolling NRG-HN014 trial. The phase III trial’s primary objective is to determine whether neoadjuvant immunotherapy with cemiplimab-rwlc combined with response-adapted oncologic surgery improves site-reported event-free survival compared to standard-of-care surgery in resectable stage III/IV cutaneous squamous cell carcinoma (CSCC). 

For more information, visit ClinicalTrials.gov (identifier NCT06568172).